S.R.Y (MEDICAL SERVICES) LTD | ש.ר.י (שרותים רפואיים) בע״מ

What S.R.Y (MEDICAL SERVICES) LTD | ש.ר.י (שרותים רפואיים) בע״מ does

S.R.Y (Medical Services) Ltd is an Israeli private company, wholly-owned by Hadassah Medical Organization, that manufactures radiopharmaceuticals for PET imaging and targeted radiotherapy. The company operates two cyclotrons simultaneously at the Hadassah Ein Kerem Hospital campus in Jerusalem—the only dual-cyclotron configuration in Israel—producing a portfolio of 12+ agents across three isotope families: 18F (FDG, PSMA-1007, NOTA-TIDE, FDOPA, Vizamyl, mFBG, FDHT, FAPI-74, FES), 68Ga (PSMA-11, DOTA-TATE), and 177Lu (LuNET-SRY). Production takes place in GMP-certified Grade A isolator clean rooms built with a 13 million NIS investment, and includes eight automatic synthesis modules supporting around-the-clock, seven-day-a-week manufacturing at approximately 8 batches per day.

The company sells finished radiopharmaceutical products directly to approximately 12 Israeli hospital nuclear medicine departments, including its parent Hadassah Ein Kerem plus Sheba, Ichilov, Assuta, Beilinson, Shaare Zedek, Carmel, Barzilai, Emek, Bnei Zion, Mayanei Hayeshua, and Augusta Victoria. It holds an exclusive six-year contract with GE Healthcare to produce and market Vizamyl (18F-florbetaben) for Alzheimer's imaging in Israel. Revenue is generated through direct B2B supply contracts with hospitals under routine daily production for standard agents and on-demand production for specialized compounds; pricing is not publicly disclosed.

The company was founded by Prof. Eyal Mishani in 1996 as Israel's first cyclotron unit and was formally incorporated as a Hadassah subsidiary in 2016. It operates with a small team (~9–15 personnel) covering leadership, manufacturing, QA, QC, R&D, maintenance, radiation safety, administration, and sales. Its competitive positioning rests on regulatory certification (GMP from Israeli Ministry of Health, EU and FDA standards), capital-intensive dual-cyclotron infrastructure, 25+ years of accumulated radiochemistry expertise, and exclusive production of first-in-Israel PET agents and branded products such as Vizamyl and LuNET-SRY.

Name

S.R.Y (MEDICAL SERVICES) LTD | ש.ר.י (שרותים רפואיים) בע״מ

Legal name

ש.ר.י (שרותים רפואיים) בע״מ

Website

https://sryms.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

S.R.Y (Medical Services) Ltd is an Israeli radiopharmaceutical manufacturer and wholly-owned subsidiary of Hadassah Medical Organization, operating two cyclotrons at Hadassah Ein Kerem Hospital to produce 18F, 68Ga, and 177Lu PET imaging and therapeutic agents for direct supply to hospital nuclear medicine departments across Israel.

Ownership category

akta.pro rank

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Radiopharmaceutical Product Sales: S.R.Y. manufactures and sells radiopharmaceutical products (18F, 68Ga, 177Lu-based PET agents and therapeutic radiopharmaceuticals) to hospital nuclear medicine departments and medical centers across Israel. Products include FDG, PSMA-1007, NOTA-TIDE, mFBG, FES, Vizamyl, DOTA-TATE, PSMA-11, and LuNET-SRY. Revenue is generated through direct supply contracts with hospitals, with routine daily production for standard products and on-demand production for specialized agents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

No descriptive content with a verifiable source identifier was provided in the input; the core offering cannot be characterized beyond the legal-entity name "Medical Services Ltd."

Product overview

S.R.Y. is a radiopharmaceutical manufacturer and developer specializing in products for PET (Positron Emission Tomography) imaging and targeted radiotherapy. The product portfolio includes three main isotope families: 18F products (FDG, PSMA-1007, NOTA-TIDE, FDOPA, Vizamyl, mFBG, FDHT, FAPI-74, FES), 68Ga products (PSMA-11, DOTA-TATE), and 177Lu products (LuNET-SRY). The company operates cyclotron facilities at Hadassah Ein Kerem Hospital to produce medical isotopes, offering both diagnostic imaging agents and therapeutic radiopharmaceuticals. The products serve oncology (cancer diagnosis and treatment), neurology (Alzheimer's diagnosis, Parkinson's imaging), and theragnostics applications combining diagnosis with targeted therapy.

Differentiator

Problem solved

Functional benefit

Brands

• LuNET-SRY: Lutetium [177Lu]oxodotreotide solution for infusion used in treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Quantifiable outcome

• 70% improvement in tumor detection resolution with new digital PET-CT technology (detecting tumors as small as 2-3 mm)
• +2 more outcomes

Named customers12 records

Segments3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• GE Healthcare (General Electric)coreOEM/ Whitelabel/ Licensing PartnerS.R.Y. holds a six-year exclusive contract with GE Healthcare to produce and market Vizamyl (18F-florbetaben), a radioactive diagnostic agent for PET brain imaging to estimate beta-amyloid neuritic plaque density in patients with cognitive impairment being evaluated for Alzheimer's disease or other causes of cognitive decline. S.R.Y. is the exclusive producer of this compound in Israel.
• Hadassah Medical Organization (Ein Kerem Hospital)coreStrategic or Co-development PartnerS.R.Y. is a wholly-owned subsidiary of Hadassah Ein Kerem Hospital. The company operates the cyclotron unit at Hadassah Ein Kerem and produces medical isotopes in its advanced nuclear pharmacy on the hospital campus. Hadassah CEO Prof. Zeev Rotstein attended the inauguration of S.R.Y.'s new production facility.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/s-r-y-m-s

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S.R.Y (MEDICAL SERVICES) LTD | ש.ר.י (שרותים רפואיים) בע״מ